JP2016535753A - Method of treating cancer and cancer comorbidities - Google Patents

Method of treating cancer and cancer comorbidities Download PDF

Info

Publication number
JP2016535753A
JP2016535753A JP2016528184A JP2016528184A JP2016535753A JP 2016535753 A JP2016535753 A JP 2016535753A JP 2016528184 A JP2016528184 A JP 2016528184A JP 2016528184 A JP2016528184 A JP 2016528184A JP 2016535753 A JP2016535753 A JP 2016535753A
Authority
JP
Japan
Prior art keywords
species
extract
cancer
comorbidities
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016528184A
Other languages
Japanese (ja)
Other versions
JP6742904B2 (en
JP2016535753A5 (en
Inventor
アルティ サード
アルティ サード
リュー ジアウェイ
リュー ジアウェイ
Original Assignee
レガシー ヘルスケア リミテッド
レガシー ヘルスケア リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レガシー ヘルスケア リミテッド, レガシー ヘルスケア リミテッド filed Critical レガシー ヘルスケア リミテッド
Publication of JP2016535753A publication Critical patent/JP2016535753A/en
Publication of JP2016535753A5 publication Critical patent/JP2016535753A5/ja
Application granted granted Critical
Publication of JP6742904B2 publication Critical patent/JP6742904B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

【課題】ガン及びガン共存症を治療する方法の提供。【解決手段】クエルセチンを含んでいてもよいアリウム種の抽出物、シトラス種の抽出物、パウリニア種の抽出物、及びテオブロマ種の抽出物を活性成分として含んでいる組成物を、従来の投与法及び非従来の経口、局所適用、非経口経路、及び腫瘍内注射、又はそれらの組合せによる投与、又は前記経路を使用する他の治療における補助増強剤としての投与することを含む、ガン並びにガン関連疲労、悪質液、食欲減退、疼痛、貧血、無力症、鬱病、筋肉力低下、吐気、嘔吐、皮膚及び皮膚付随組織損傷に例示されるガン共存症の治療方法を提供する。【選択図】なしA method for treating cancer and cancer comorbidities is provided. A composition comprising an extract of allium species, citrus species extract, paulinia species extract, and theobroma species extract, which may contain quercetin, as an active ingredient. And non-conventional oral, topical application, parenteral route, and administration by intratumoral injection, or combinations thereof, or administration as an adjunct enhancer in other treatments using the route, and cancer-related Provided is a method for treating cancer comorbidities exemplified by fatigue, malicious fluid, loss of appetite, pain, anemia, asthenia, depression, muscle weakness, nausea, vomiting, skin and skin-associated tissue damage. [Selection figure] None

Description

本発明は、ガン及びガン共存症を治療する方法に関する。本発明が対象とするガン共存症は、ガン関連疲労、悪質液、食欲減退、疼痛、貧血、無力症、鬱病、認知能力低下、筋肉力低下、吐気、嘔吐、関節炎、臓器損傷、放射線誘発熱傷、化学及び放射線治療による心臓障害、高血圧症、血栓塞栓症、間歇性胸痛、呼吸困難症、呼吸短縮症、めまい、失神、皮膚又は唇の蒼白化、頭痛、集中力減退、不眠症、体温維持困難症、出血、爪損傷、過敏性皮膚及び乾燥皮膚、潰瘍及び乾燥口に例示される皮膚及び皮膚付随組織損傷等であるが、これらに限定されない。   The present invention relates to cancer and methods for treating cancer comorbidities. Cancer comorbidities targeted by the present invention are cancer-related fatigue, vicious fluid, decreased appetite, pain, anemia, asthenia, depression, cognitive decline, muscle weakness, nausea, vomiting, arthritis, organ damage, radiation-induced burns , Heart failure due to chemical and radiotherapy, hypertension, thromboembolism, intermittent chest pain, dyspnea, respiratory distress, dizziness, fainting, pale skin or lips, headache, loss of concentration, insomnia, maintenance of body temperature Examples include, but are not limited to, dysfunction, bleeding, nail damage, sensitive skin and dry skin, ulcers and skin-related tissue damage exemplified by dry mouth.

従来、ガンの主要な治療法は、制御のできない細胞の増殖を抑制することであった。然しながら、腫瘍の増殖メカニズムは、多岐にわたる複雑な側面をもっているので、多種多様なガンの治療法を考えて、ガン治療において解決されずに残っている課題、特に重要なことは、ガン治療に伴う副作用を緩和しなければならない。従来の研究によって、炎症細胞及び炎症促進性分子が、主として、腫瘍の成長及び促進に関与することが分かっている。実験段階では、炎症分子（例えば、サイトカイン）の減少が、ガンの増殖を抑制することが分かっている。最近の研究に基づけば、炎症の抑制が、ガンの管理に寄与すると考えられる。従って、「悪性炎症」を制御すること、又は減少させることが、非常に重要なガンの管理法になると考えられる。   Traditionally, the primary treatment for cancer has been to suppress uncontrolled cell growth. However, since the mechanism of tumor growth has a wide variety of complex aspects, considering various cancer treatment methods, the remaining issues that remain unsolved in cancer treatment, particularly important, are associated with cancer treatment. Side effects must be alleviated. Previous studies have shown that inflammatory cells and pro-inflammatory molecules are primarily responsible for tumor growth and promotion. At the experimental stage, a decrease in inflammatory molecules (eg, cytokines) has been shown to suppress cancer growth. Based on recent research, suppression of inflammation may contribute to cancer management. Therefore, controlling or reducing “malignant inflammation” is considered to be a very important cancer management method.

抗ガン治療は、患者の寿命を延長してきた。然しながら、ガン関連及びガン治療関連共存症が、ガン患者の余命にとって、喫緊の課題になってきている。上述した疾病は、抗癌剤の最も危険な副作用であり、その結果、クオリティー・オブ・ライフ（QOL）が低下し、余命年数を短くしていることが懸念される。   Anti-cancer treatment has extended the lifespan of patients. However, cancer-related and cancer treatment-related comorbidities are becoming an urgent issue for the life expectancy of cancer patients. The above-mentioned diseases are the most dangerous side effects of anticancer drugs, and as a result, there is concern that the quality of life (QOL) is reduced and the life expectancy is shortened.

無力疲労症候群(AFS)又はガン関連疲労は、ガンの治療中及び治療後、ガン患者が通常罹る症状で、病的疲労、忍耐力低下並びに運動及び認知機能低下である。この症状は、患者により固体差が大きく、症状を認識し難いので、確定することが難しい。ガン学会では、上述した共存症が、どのようにして、ガン関連疲労症を重篤にするのかに関して、幾つかの報告が提出されている。   Helpless Fatigue Syndrome (AFS) or cancer-related fatigue is a condition that cancer patients usually suffer during and after cancer treatment, such as morbidity, decreased patience, and decreased motor and cognitive function. This symptom is difficult to determine because there are large differences among patients and it is difficult to recognize the symptom. The Cancer Society has submitted several reports on how the above-mentioned comorbidities make cancer-related fatigue serious.

或る研究団体が、ガン関連疲労は、炎症誘発性サイトカインネットワークの活性により加速される、という仮説を試験したことがある。事実、炎症は、ガン治療の前、治療中、及び治療後に、ガン関連疲労症において重要な役割を担っていると考えられる。従って、持続性の炎症経路を制御又は低減すれば、ガン関連疲労の治療に有効と思われる。   A research group has tested the hypothesis that cancer-related fatigue is accelerated by the activity of pro-inflammatory cytokine networks. In fact, inflammation is thought to play an important role in cancer-related fatigue before, during and after cancer treatment. Thus, controlling or reducing the persistent inflammatory pathway may be effective in treating cancer-related fatigue.

ガン患者の持続性病理症状が、炎症誘発性媒体/サイトカインの発現上昇を促進させ、且つ、全身の慢性炎症を高レベルに維持し、ガンの共存症を引き起こす重要な原因になる。   Persistent pathological symptoms in cancer patients are an important cause of promoting increased expression of pro-inflammatory media / cytokines and maintaining systemic chronic inflammation at high levels, causing cancer comorbidities.

現在のガン治療では、抗ガン性化学剤が、増殖中のガン細胞を急速に破壊し、同時に、正常細胞をも破壊し、それらが、化学治療剤及び放射線治療による攻撃でアポトーシスになる。その結果、非常に多くのガン性細胞の大量のアポトーシスが、二次壊死する。これらの壊死性細胞が、炎症促進性分子の生産を刺激して、炎症を誘発し、持続させる。   In current cancer therapies, anti-cancer chemicals rapidly destroy proliferating cancer cells and at the same time destroy normal cells, which become apoptotic upon attack by chemotherapeutic agents and radiation therapy. As a result, massive apoptosis of so many cancerous cells results in secondary necrosis. These necrotic cells stimulate the production of pro-inflammatory molecules to induce and sustain inflammation.

多くの内部要因及び外部要因が、長期の炎症の原因になる。然しながら、ヒト血管系の活性化された血管内皮細胞（ECs）は、直接血液と接触しているので、急性及び慢性炎症の進行に重要な役を担っている。従って、血管内皮細胞が、ガン及びガン共存症を治療するための代表的な対象である。ここに、ガン共存症は、ガン関連疲労、悪質液、食欲減退、疼痛、貧血、無力症、鬱病、筋力低下、吐気、嘔吐、皮膚及び皮膚付随組織損傷等であるが、これらに限定されない。   Many internal and external factors cause long-term inflammation. However, activated vascular endothelial cells (ECs) of the human vasculature play an important role in the progression of acute and chronic inflammation because they are in direct contact with blood. Accordingly, vascular endothelial cells are representative subjects for treating cancer and cancer comorbidities. Here, cancer comorbidities include, but are not limited to, cancer-related fatigue, malicious fluid, loss of appetite, pain, anemia, asthenia, depression, muscle weakness, nausea, vomiting, skin and skin-related tissue damage, and the like.

腫瘍の発生原因に関与する可能性があるメカニズムの一つは、サイトカイン（例、インターロイキン８）及び付着分子、例えば、ICAM-1（細胞間分子-１、いわゆるCD54）, E-セレクチン/ELAM-1(いわゆる、CD62E)のような炎症誘発性媒体の増大した発現である。付着分子は、全脈管系の内表面に沿っている内皮細胞膜に低濃度で存在している。それらの発現レベルは、炎症誘発経路に必須である。このような炎症誘発性分子の発現が低レベルの場合は、炎症が低度であり、逆に発現が高レベルの場合は、炎症状態が増大していることを示している。毒性又は病理学的損傷があると、生産されたＴＮＦ-α（腫瘍壊死因子)が、付着分子、並びにE−セレクチン、ICAM-1及びインターロイキン８（IL-８）に例示されるサイトカインの発現を大幅に刺激する。付着分子及びサイトカインの発現が増大すると、白血球が漸増し、炎症部位へ免疫反応と炎症反応を起こし、炎症部位の脈管内皮を貫通する炎症細胞を湿潤させる。   One mechanism that may be involved in the pathogenesis of tumors is cytokines (eg, interleukin 8) and adhesion molecules such as ICAM-1 (intercellular molecule-1, so-called CD54), E-selectin / ELAM Increased expression of pro-inflammatory media such as -1 (so-called CD62E). Adhesion molecules are present at low concentrations in the endothelial cell membrane along the inner surface of the entire vascular system. Their expression level is essential for the pro-inflammatory pathway. A low level of expression of such pro-inflammatory molecules indicates a low level of inflammation, while a high level of expression indicates an increased inflammatory condition. In the presence of toxic or pathological damage, the produced TNF-α (tumor necrosis factor) is an adhesion molecule and the expression of cytokines exemplified by E-selectin, ICAM-1 and interleukin 8 (IL-8) Greatly stimulates. As the expression of adhesion molecules and cytokines increases, leukocytes gradually increase, causing immune and inflammatory responses to the inflammatory site, and moistening inflammatory cells that penetrate the vascular endothelium at the inflammatory site.

或る研究によれば、対照テストの結果、末期の肺ガン患者の可溶性Ｅ−セレクチン及びICAM-１が顕著に増大することを示していた。さらに、増大した付着分子レベルが、生存率の減少を示していた。さらに、種々の炎症誘発性媒体が、腫瘍発生炎症脈管新生において、本質的に脈管内皮成長因子で制御される経路を変換するだけではなく、腫瘍転移を促進させる。従って、有害な炎症を減少させるには、これらの炎症誘発性分子の生成を制限し、異常な炎症反応を減衰させることが必須である。   According to one study, control tests showed that soluble E-selectin and ICAM-1 were significantly increased in end-stage lung cancer patients. Furthermore, increased adhesion molecule levels showed a decrease in viability. Furthermore, various pro-inflammatory media not only transduce pathways that are essentially regulated by vascular endothelial growth factor in tumorigenic inflammatory angiogenesis, but also promote tumor metastasis. Therefore, to reduce harmful inflammation, it is essential to limit the production of these pro-inflammatory molecules and attenuate abnormal inflammatory responses.

本発明者の研究によれば、分子レベルで、後述する成分を含む組成物は抗炎症剤で、HUVECs(ヒト臍静脈内皮細胞)におけるE-セレクチン及び付着分子ICAM-1のＴＮＦα誘発発現及びサイトカインIL-8発現を低減することができることを示している。このような抗炎症作用は、腫瘍の増殖を抑制し、且つ、腫瘍のサイズを小さくする（参照：上述した記載及びイン・ビトロ及びイン・ビボ両方の実験から得た実施例のデータ）。従って、後述する成分を含む組成物は抗炎症効果を有していて、ガン及びガン共存症の治療に寄与する。   According to the study of the present inventor, at the molecular level, the composition comprising the components described below is an anti-inflammatory agent, and TNFα-induced expression and cytokine of E-selectin and adhesion molecule ICAM-1 in HUVECs (human umbilical vein endothelial cells) It shows that IL-8 expression can be reduced. Such anti-inflammatory action suppresses tumor growth and reduces tumor size (see: description above and example data obtained from both in vitro and in vivo experiments). Therefore, the composition containing the components described later has an anti-inflammatory effect and contributes to the treatment of cancer and cancer comorbidities.

後述する成分を含む組成物は、無作為実験で、マウスのモデル・ガンに皮下注射で投与された。非処理マウスと比較して結果、前記組成物は、処理したマウスの腫瘍の成長とサイズを抑制することが観察された（参照：イン・ビトロ及びイン・ビボ両方の実験から得た実施例２のデータ）。   A composition containing the components described below was administered by subcutaneous injection to a mouse model cancer in a randomized experiment. As a result, compared to untreated mice, the composition was observed to suppress tumor growth and size in treated mice (see: Example 2 from both in vitro and in vivo experiments). data from).

後述する成分を含む組成物は、化学剤治療によって誘発される脱毛を防ぐために局所用製剤としてガン患者に投与された。患者の中には、脱毛現象が起きなかった効果の他に、それまで患者を苦しめていた疲労のような他の諸症状が確実に改善され始めた、と報告した者もいた。   A composition comprising the components described below was administered to cancer patients as a topical formulation to prevent hair loss induced by chemical treatment. Some patients reported that, in addition to the effects of no hair loss, other symptoms such as fatigue that had previously suffered patients began to improve steadily.

発明が解決しようとする課題は、ガン及びガン共存症を治療する方法及びそれに使用する組成物を提供することである。   The problem to be solved by the invention is to provide a method of treating cancer and cancer comorbidities and a composition for use therein.

後述する成分を含む組成物は、肝臓ガンに罹患している患者に経口投与される。内科医及び患者の報告、並びに前記組成物を摂取した前後の画像に基づくと、ガン関連疲労の緩和を含め、患者の病状は大幅に改善している。   A composition containing the components described below is orally administered to a patient suffering from liver cancer. Based on physician and patient reports and images before and after taking the composition, the patient's condition, including alleviation of cancer-related fatigue, has improved significantly.

クエルセチンを含んでいてもよいアリウム種(Allium species)の抽出物、シトラス種(Citrus species)の抽出物、パウリニア種(Paullinia species)の抽出物、及びテオブロマ種(Theobroma species) の抽出物を活性成分として含んでいる組成物を、経口、局所、又は非経口、腫瘍内注射、又はそれらの組合せによって投与すると、ガンの管理とガン共存症の治療に新規な効果を奏功することが観察された。   Allium species extract, Citrus species extract, Paulinia species extract and Theobroma species extract, which may contain quercetin, as active ingredients It has been observed that when the composition comprising is administered orally, topically, or parenterally, intratumoral injection, or a combination thereof, it has a novel effect in managing cancer and treating cancer comorbidities.

本発明は、クエルセチンを含んでいてもよいアリウム種(Allium species)の抽出物、シトラス種(Citrus species)の抽出物、パウリニア種(Paullinia species)の抽出物、及びテオブロマ種(Theobroma species) の抽出物を活性成分として含んでいる組成物を、従来法による投与及び非従来による投与方法の両方による投与、又は細胞療法の補助増強剤として、又は局所投与、又は非経口投与、又は腫瘍内注射、又はそれらの組合せによって投与することを含む、ガンの管理方法及びガン関連疲労、悪質液、食欲減退、疼痛、貧血、無力症、鬱病、筋肉力低下、吐気、嘔吐、皮膚及び皮膚付随組織損傷に例示されるガン共存症の治療方法を提供する。   The present invention relates to an extract of Allium species, which may contain quercetin, an extract of Citrus species, an extract of Paulinia species, and an extraction of Theobroma species. A composition containing the product as an active ingredient, administered by both conventional and non-conventional administration methods, or as an adjuvant enhancer for cell therapy, or topically or parenterally, or intratumoral injection, Or by a combination thereof, for cancer management methods and cancer-related fatigue, vicious fluid, loss of appetite, pain, anemia, asthenia, depression, muscle weakness, nausea, vomiting, skin and skin-related tissue damage An exemplary method for treating cancer comorbidities is provided.

本発明により、脱毛等の副作用をもたらすことなく、各種のガン、及びガン関連疲労、悪質液、食欲減退、疼痛、貧血、無力症、鬱病、認知能力低下、筋肉力低下、吐気、嘔吐、関節炎、臓器損傷、放射線誘発熱傷、化学及び放射線治療による心臓障害、高血圧症、血栓塞栓症、間歇性胸痛、呼吸困難症、呼吸短縮症、めまい、失神、皮膚又は唇の蒼白化、頭痛、集中力減退、不眠症、体温維持困難症、出血、爪損傷、過敏性皮膚及び乾燥皮膚、潰瘍及び乾燥口に例示される皮膚及び皮膚付随組織損傷に例示されるガン共存症の治療をすることができる。   According to the present invention, without causing side effects such as hair loss, various cancers and cancer-related fatigue, malicious fluid, loss of appetite, pain, anemia, asthenia, depression, cognitive decline, muscle weakness, nausea, vomiting, arthritis , Organ damage, radiation-induced burn, heart damage due to chemistry and radiation therapy, hypertension, thromboembolism, intermittent chest pain, dyspnea, respiratory shortening, dizziness, fainting, pale skin or lips, headache, concentration Can treat cancer complications exemplified by decline, insomnia, difficulty in maintaining body temperature, bleeding, nail damage, sensitized and dry skin, ulcers and skin-related tissue damage exemplified by dry mouth .

時間毎に測定した平均体重（gr）を示すグラフ。The graph which shows the average body weight (gr) measured for every time. 時間毎に測定した平均腫瘍体積（mm3）を示すグラフ。The graph which shows the average tumor volume (mm < 3 >) measured every time.

本発明は、クエルセチンを含んでいてもよいアリウム種(Allium species)の抽出物、シトラス種(Citrus species)の抽出物、パウリニア種(Paullinia species)の抽出物、及びテオブロマ種(Theobroma species) の抽出物を活性成分として含んでいる組成物を、経口、局所、又は非経口、又は腫瘍内注射、又はそれらの組合せによって投与することを含む、ガン、並びにガン関連疲労、悪質液、食欲減退、疼痛、貧血、無力症、鬱病、認知能力低下、筋肉力低下、吐気、嘔吐、関節炎、臓器損傷、放射線誘発熱傷、化学及び放射線治療による心臓障害、高血圧症、血栓塞栓症、間歇性胸痛、呼吸困難症、呼吸短縮症、めまい、失神、皮膚又は唇の蒼白化、頭痛、集中力減退、不眠症、体温維持困難症、出血、爪損傷、過敏性皮膚及び乾燥皮膚、潰瘍及び乾燥口に例示される皮膚及び皮膚付随組織損傷に例示されるガン共存症を治療する方法に関する。   The present invention relates to an extract of Allium species, which may contain quercetin, an extract of Citrus species, an extract of Paulinia species, and an extraction of Theobroma species. Cancer, including cancer, as well as cancer-related fatigue, vicious fluid, loss of appetite, pain, including administering a composition containing the product as an active ingredient by oral, topical, or parenteral, or intratumoral injection, or a combination thereof , Anemia, asthenia, depression, cognitive decline, muscle weakness, nausea, vomiting, arthritis, organ damage, radiation-induced burn, heart damage due to chemical and radiotherapy, hypertension, thromboembolism, intermittent chest pain, respiratory distress Exacerbations, respiratory shortening, dizziness, fainting, pale skin or lips, headache, reduced concentration, insomnia, difficulty maintaining body temperature, bleeding, nail damage, irritable and dry skin, ulcers and dry mouth That relates to a method of treating skin and cancer comorbidities illustrated in skin associated tissue damage.

本発明によるガン及びガン共存症を治療する方法の中でも、４つの活性成分の全質量基準で、クエルセチンを含んでいるアリウム種(Allium species)の抽出物を３０〜９３質量％；シトラス種(Citrus species)の抽出物を３〜３３質量％；パウリニア種(Paullinia species)の（微粒化した、又はしていない）抽出物を０．１０〜２．５質量％；及びテオブロマ種(Theobroma species)の（微粒化した、又はしていない）抽出物を０．１０〜２．５質量％含んでいる組成物が、特に重要である。   Among the methods for treating cancer and cancer complications according to the present invention, 30-93% by weight of an extract of Allium species containing quercetin, based on the total mass of the four active ingredients; Citrus species 3) to 33% by weight of the extract of the species; 0.10 to 2.5% by weight of the extract of the Paulinia species (micronized or not); and the theobroma species Of particular importance are compositions containing 0.10 to 2.5% by weight of extract (either atomised or not).

本発明の一態様においては、前記組成物は、組成物の全質量基準で、アリウム種(Allium species)のクエルセチンを含んでいる抽出物を３０〜９３質量％；シトラス種(Citrus species)の抽出物を３〜３３質量％；パウリニア種(Paullinia species)の（微粒化した、又はしていない）抽出物を０．１０〜２．５質量％；及びテオブロマ種(Theobroma species)の（微粒化した、又はしていない）抽出物を０．１０〜２．５質量％；塩化ナトリウムを０．５〜３．０質量％；及びグリセリンを２５〜５０質量％含んでいる。   In one embodiment of the present invention, the composition comprises 30-93% by weight of an extract containing arcetin of Allium species, based on the total weight of the composition; extraction of Citrus species From 3 to 33% by weight; from 0.10 to 2.5% by weight (pulverized or not) extract of Paulinia species; and from theobroma species (micronized) 0.10-2.5% by weight extract); 0.5-3.0% by weight sodium chloride; and 25-50% by weight glycerin.

本発明によるガン及びガン共存症を治療する方法の中でも、前記組成物を、通常の経口投与組成物、注射用組成物、局所適用用組成物としてだけではなく、ガン及びガン共存症を治療するための補助増強剤として使用する方法が特に重要である。当該組成物は、４つの活性成分の全質量基準で、クエルセチンを含んでいるアリウム種(Allium species)の抽出物を３０〜９３質量％；シトラス種(Citrus species)の抽出物を３〜３３質量％；パウリニア種(Paullinia species)の（微粒化した、又はしていない）抽出物を０．１０〜２．５質量％；及びテオブロマ種(Theobroma species)の（微粒化した、又はしていない）抽出物を０．１０〜２．５質量％含んでいる。   Among the methods for treating cancer and cancer comorbidities according to the present invention, the composition is used not only as a normal oral administration composition, injectable composition, and composition for topical application, but also to treat cancer and cancer comorbidities. Of particular importance is the method used as an auxiliary enhancer for the purpose. The composition is 30 to 93% by weight of an extract of Allium species containing quercetin, based on the total weight of the four active ingredients; 3 to 33% by weight of an extract of Citrus species %; 0.10 to 2.5% by weight of extract of Paulinia species (micronized or not); and of Theobroma species (micronized or not) The extract contains 0.10 to 2.5% by mass.

本発明の一態様においては、前記組成物は、４つの活性成分の全質量基準で、アリウム・セパ（Allium cepa）の抽出物を３０〜９３質量％；シトラス・レモン(Citrus lemon)の抽出物を３〜３３質量％；パウリニア種(Paullinia species)の（微粒化した、又はしていない）抽出物を０．１０〜２．５質量％；及びテオブロマ種(Theobroma species)の（微粒化した、又はしていない）抽出物を０．１０〜２．５質量％含んでいる。   In one embodiment of the invention, the composition comprises 30-93% by weight of an extract of Allium cepa, based on the total weight of the four active ingredients; an extract of Citrus lemon 3 to 33% by weight; 0.10 to 2.5% by weight (pulverized or not) extract of Paulinia species; and Theobroma species (micronized, It contains 0.10 to 2.5% by weight of extract).

本発明の一態様においては、前記組成物は、組成物の全質量基準で、クエルセチンを含んでいるアリウム種(Allium species)の抽出物を３０〜９３質量％；シトラス種(Citrus species)の抽出物を３〜３３質量％；パウリニア種(Paullinia species)の（微粒化した、又はしていない）抽出物を０．１０〜２．５質量％；テオブロマ種(Theobroma species)の（微粒化した、又はしていない）抽出物を０．１０〜２．５質量％；塩化ナトリウムを０．５〜３．０質量％；及びグリセリンを２５〜５０質量％含んでいる。   In one embodiment of the invention, the composition comprises 30-93% by weight of an extract of Allium species containing quercetin, based on the total weight of the composition; extraction of Citrus species From 3 to 33% by weight; from 0.10 to 2.5% by weight (pulverized or not) of Paulinia species; from theobroma species (micronized, Or not) contains 0.10-2.5% by weight extract; 0.5-3.0% by weight sodium chloride; and 25-50% by weight glycerin.

用語「アリウム種(Allium species)の抽出物」は、特に、アリウム（Allium）属（ユリ科）の総ての種、特にタマネギ（Allium cepa）から得られた抽出物及び純粋抽出物を意味し、クエルセチンを含んでいてもよい。用語「シトラス種(Citrus species)の抽出物」は、特に、シトラス(Citrus）属（ミカン(Rutaceae)科）の総ての種、特にレモン(Citrus lemon)から得られた抽出物及び純粋抽出物を意味する。用語「パウリニア種(Paullinia species)の（微粒化した、又はしていない）抽出物」は、特に、パウリニア属（ムクロジ科[サピンダシア(Sapindaceae)]の総ての種、特にパウリニア・クパナ(Paullinia cupana）から得られた抽出物及び純粋抽出物を意味する。用語「テオブロマ種(Theobroma species)の（微粒化した、又はしていない）抽出物」は、特に、テオブロマ属[マルヴェシア科(Malvaceae)]の総ての種、特にテオブロマ・カカオ(Theobroma cacao)から得られた水性アルコール抽出物及び純粋抽出物を意味する。   The term “allium species extract” means in particular extracts and pure extracts obtained from all species of the genus Allium (Liliaceae), in particular onions (Allium cepa). And may contain quercetin. The term “extract of Citrus species” refers in particular to extracts and pure extracts obtained from all species of the genus Citrus (Rutaceae family), in particular Citrus lemon Means. The term “extracted (not atomised) of Paulinia species” refers in particular to all species of the genus Paurinia (Muclidaceae [Sapindaceae), in particular Paulinia cupana. The term “theobroma species (micronized or not) extract” particularly refers to the genus Theobroma [Malvaceae]. Means hydroalcoholic extracts and pure extracts obtained from all the species, especially Theobroma cacao.

本発明で使用される最も好ましい組成物は、４つの活性成分の全質量基準で、クエルセチンを含むアリウム・セパ（Allium cepa）の抽出物を約８７質量％；シトラス・レモン(Citrus lemon)の抽出物を約１２質量％；パウリニア・クパナ(Paullinia cupana)の（微粒化した、又はしていない）抽出物を約０．５質量％；及びテオブロマ・カカオ(Theobroma cacao)の（微粒化した、又はしていない）抽出物を約０．５質量％含んでいる。   The most preferred composition used in the present invention is about 87% by weight extract of Allium cepa containing quercetin, based on the total weight of the four active ingredients; extraction of Citrus lemon About 12% by weight of extract; about 0.5% by weight of extract of Paulininia cupana (micronized or not); and of Theobroma cacao (micronized or It contains about 0.5% by weight of extract.

本発明によると、当該組成物は、クエルセチンを含んでいるアリウム種(Allium species)の抽出物、シトラス種(Citrus species)の抽出物、及びパウリニア種(Paullinia species)の抽出物、及びテオブロマ種(Theobroma species)の抽出物を、活性成分として含む混合物状態で連続投与される。   According to the present invention, the composition comprises an extract of Allium species containing quercetin, an extract of Citrus species, and an extract of Paulinia species, and theobroma species ( Theobroma species) extract is continuously administered in a mixture containing the active ingredient.

本発明の一態様によると、当該組成物は、クエルセチンを含んでいるアリウム種(Allium species)の抽出物、シトラス種(Citrus species)の抽出物、及びパウリニア種(Paullinia species)の抽出物、及びテオブロマ種(Theobroma species)の抽出物を、活性成分として含む組成物として、数カ月又はそれ以上の期間毎日投与される。   According to one aspect of the invention, the composition comprises an extract of Allium species, an extract of Citrus species, and an extract of Paulinia species containing quercetin, and An extract of Theobroma species is administered daily as a composition containing as an active ingredient for a period of several months or longer.

ガン及びガン共存症の治療の測定可能な効果を得るために、前記組成物を連続投与、好ましくは少なくとも６カ月投与する必要がある。本発明により、前記組成物を使用する場合、投与量は、比較的広範な制限域で変化することができるが、治療を受ける患者及びその状態を考慮して投与量を設定しなければならない。医薬組成物は、前記定義した活性成分を、乾燥状態で、通常、０．４〜１０００ｍｇ、好ましくは、２〜４００ｍｇ含んでいる。   In order to obtain a measurable effect of treatment of cancer and cancer comorbidities, the composition should be administered continuously, preferably at least 6 months. According to the present invention, when the composition is used, the dosage can vary within a relatively wide range, but the dosage must be set in consideration of the patient to be treated and its condition. The pharmaceutical composition usually contains 0.4 to 1000 mg, preferably 2 to 400 mg, of the above-defined active ingredient in a dry state.

さらに、本発明は、ガン並びにガン共存症、即ち、ガン関連疲労、悪質液、食欲減退、疼痛、貧血、無力症、鬱病、筋肉力低下、吐気、嘔吐、皮膚及び皮膚付随組織損傷等に例示されるガン共存症の治療に使用され、通常の投与方法及び新規な投与方法の両方の投与経路により、及び／又は細胞治療における補助増強剤として、又は局所適用、又は非経口投与、又は腫瘍内注射、又はこれらの組み合わせによる投与方法によって投与され、クエルセチンを含んでいるアリウム種(Allium species)の抽出物、シトラス種(Citrus species)の抽出物、及びパウリニア種(Paullinia species)の抽出物、及びテオブロマ種(Theobroma species)の抽出物を活性成分として含んでいる組成物に関する。   Furthermore, the present invention is exemplified for cancer and cancer comorbidities, ie, cancer-related fatigue, vicious fluid, decreased appetite, pain, anemia, asthenia, depression, muscle weakness, nausea, vomiting, skin and skin-associated tissue damage, etc. Used in the treatment of cancer comorbidities, by both the usual and novel administration routes, and / or as an adjuvant enhancer in cell therapy, or topically applied, or parenterally, or intratumoral An extract of Allium species, an extract of Citrus species, and an extract of Paulinia species, which are administered by means of injection or a combination of these and contain quercetin, and It relates to a composition comprising an extract of Theobroma species as an active ingredient.

本発明の一態様によると、ガン及びガン共存症の治療に使用される前記組成物は、クエルセチンを含んでいるアリウム種(Allium species)の抽出物、シトラス種(Citrus species)の抽出物、及びパウリニア種(Paullinia species)の（微粒化した、又はしていない）抽出物、及びテオブロマ種(Theobroma species)の（微粒化した、又はしていない）抽出物を含んでいる。   According to one aspect of the invention, the composition used for the treatment of cancer and cancer comorbidities comprises an extract of Allium species comprising quercetin, an extract of Citrus species, and It includes an extract (with or without atomization) of Paulinia species and an extract (with or without atomization) of Theobroma species.

本発明の別の態様によると、ガン及びガン共存症の治療に使用される前記組成物は、４つの活性成分の全質量基準で、アリウム種(Allium species)の抽出物を３０〜９３質量％；シトラス種(Citrus species)の抽出物を３〜３３質量％；パウリニア種(Paullinia species)の（微粒化した、又はしていない）抽出物を０．１０〜２．５質量％；及びテオブロマ種(Theobroma species)の（微粒化した、又はしていない）抽出物を０．１０〜２．５質量％含んでいる。   According to another aspect of the present invention, said composition used for the treatment of cancer and cancer comorbidities comprises 30-93% by weight of an extract of Allium species, based on the total weight of the four active ingredients. From 3 to 33% by weight of an extract of Citrus species; 0.10 to 2.5% by weight of (atomized or not) extract of Paulinia species; and theobroma species 0.10 to 2.5% by weight of (Theobroma species) (atomized or not) extract.

下記の組成物（以下「組成物Ａ」という）を、患者に、毎日、経口投与、局所適用、非経口投与、又は腫瘍内注射の単独、又はこれらの組合せにより投与した。
■アリウム・セパ（Allium cepa）の抽出物（クエルセチンを含む）：８７．０４％
■シトラス・レモン(Citrus lemon)の抽出物：１１．９６％
■パウリニア・クパナ(Paullinia cupana)の微粒化抽出物：０．５０％
■テオブロマ・カカオ(Theobroma cacao)の微粒化抽出物：０．５０％
予め、ＷＯ２００８/１１３９１２に記載されている実施例１に従ってローションを製造した。組成物Ａは、４種の天然成分の混合物で、異常細胞アポトーシス及び炎症経路の欠点に好影響を与えると報告されている。このことは、組成物Ａが、前述したガン及びガン共存症の治療に積極的な影響を与えることができるということを示している。 The following composition (hereinafter “Composition A”) was administered to patients daily by oral administration, topical application, parenteral administration, or intratumoral injection alone, or a combination thereof.
■ Allium cepa extract (including quercetin): 87.04%
■ Citrus lemon extract: 11.96%
■ Paullinia cupana atomized extract: 0.50%
■ Theobroma cacao atomized extract: 0.50%
A lotion was prepared in advance according to Example 1 described in WO2008 / 113912. Composition A has been reported to be a mixture of four natural ingredients that positively affect the abnormal cell apoptosis and defects of the inflammatory pathway. This indicates that composition A can positively influence the treatment of cancer and cancer comorbidities described above.

炎症促進性分子の抑制ＴＮＦα-誘発性発現を介した、アリウム種(Allium species)の抽出物（クエルセチンを含んでいる）、シトラス種(Citrus species)の抽出物、パウリニア種(Paullinia species)の抽出物、及びテオブロマ種(Theobroma species)の抽出物を活性成分として含む組成物の抗炎症効果に対する試験を行った。炎症促進性分子は、表2a、2b、及び2cに記載したようにICAM-1、E-セレクチン、及びインターロイキンである。試験した組成物を表１に示した。   Inhibition of pro-inflammatory molecules Extraction of Allium species (including quercetin), Citrus species, Paulinia species via TNFα-induced expression And an anti-inflammatory effect of a composition containing an extract of Theobroma species as an active ingredient. Proinflammatory molecules are ICAM-1, E-selectin, and interleukin as described in Tables 2a, 2b, and 2c. The tested compositions are shown in Table 1.

表１：試験した組成物

Figure 2016535753
Table 1: Compositions tested
Figure 2016535753

表２a:内皮細胞（HUVECs)の表面の付着分子ICAM-1(CD54)の発現に対する「組成物」の効果

Figure 2016535753
＊細胞に結合している特定の抗体
Table 2a: Effect of “composition” on expression of adhesion molecule ICAM-1 (CD54) on the surface of endothelial cells (HUVECs)
Figure 2016535753
* Specific antibodies bound to cells

表２ｂ:内皮細胞（HUVECs)の表面の付着分子E-セレクチン/ELAM-1(CD62E)の発現に対する「組成物」の効果

Figure 2016535753
＊細胞に結合している特定の抗体
Table 2b: Effect of “composition” on the expression of adhesion molecules E-selectin / ELAM-1 (CD62E) on the surface of endothelial cells (HUVECs)
Figure 2016535753
* Specific antibodies bound to cells

表２ｃ:内皮細胞（HUVECs)によるサイトカインインターロイキン８（IL-8）の発現に対する「組成物」の効果

Figure 2016535753
＊細胞に結合している特定の抗体 Table 2c: Effect of “Composition” on Expression of Cytokine Interleukin 8 (IL-8) by Endothelial Cells (HUVECs)
Figure 2016535753
* Specific antibodies bound to cells

タイプＫＢの皮下ヒト腫瘍を植付けたヌード・マウスを使用した新組成物の抗腫瘍活性の検討
図１は、タイプＫＢのヒト皮下腫瘍を植付けたヌード・マウスの平均体重のカーブを示している。マウスを７日間で無作為化し、それぞれ０．３％及び１．０％の組成物溶液（ＴＨＩ）１００μＬを、連続５日間毎日注射した。 Examination of Antitumor Activity of New Composition Using Nude Mice Implanted with Type KB Subcutaneous Human Tumor FIG. 1 shows a curve of average body weight of nude mice implanted with type KB human subcutaneous tumor. Mice were randomized for 7 days and 100 μL of 0.3% and 1.0% composition solution (THI), respectively, were injected daily for 5 consecutive days.

図１において：ｘ軸は、時間（日数）を、ｙ軸は、ヌード・マウスの平均体重（g）を表わしている；青（カーブ２）は、対照ビヒクルを表わしている；ピンク（カーブ３）は、０．３％組成物（ＴＨＩ）を表わしている；黄色（カーブ１）は、０．１％組成物（ＴＨＩ）を表わしている。顕著な体重変化は見られなかった。   In FIG. 1: the x-axis represents time (days), the y-axis represents the average body weight (g) of nude mice; blue (curve 2) represents the control vehicle; pink (curve 3) ) Represents the 0.3% composition (THI); yellow (curve 1) represents the 0.1% composition (THI). There was no significant weight change.

図２は、タイプＫＢの皮下ヒト腫瘍を植付けたヌード・マウスの平均腫瘍体積のカーブを示している。マウスを７日間で無作為化し、それぞれ０．３％及び１．０％の組成物溶液（ＴＨＩ）１００μＬを、連続５日間毎日注射した。   FIG. 2 shows a curve of the mean tumor volume of nude mice implanted with a type KB subcutaneous human tumor. Mice were randomized for 7 days and 100 μL of 0.3% and 1.0% composition solution (THI), respectively, were injected daily for 5 consecutive days.

図２において：ｘ軸は、時間（日数）を、ｙ軸は、ヌード・マウスの平均腫瘍体積（mm3）を表わしている；青（カーブ２）は、対照ビヒクルを表わしている；ピンク（カーブ３）は、０．３％組成物（ＴＨＩ）を表わしている；黄色（カーブ１）は、０．１％組成物（ＴＨＩ）を表わしている。腫瘍の体積に顕著な変化は見られなかった。 In FIG. 2: the x-axis represents time (days), the y-axis represents the mean tumor volume (mm 3 ) of nude mice; blue (curve 2) represents the control vehicle; pink ( Curve 3) represents the 0.3% composition (THI); yellow (curve 1) represents the 0.1% composition (THI). There was no significant change in tumor volume.

Claims (3)

ガン、並びにガン関連疲労、悪質液、食欲減退、疼痛、貧血、無力症、鬱病、筋肉力低下、吐気、嘔吐、皮膚及び皮膚付随組織損傷を含むガン共存症を治療する方法であって、クエルセチンを含むアリウム種(Allium species)の抽出物、シトラス種(Citrus species)の抽出物、パウリニア種(Paullinia species)の抽出物、及びテオブロマ種(Theobroma species)の抽出物を活性成分として含んでいる組成物を、従来の投与法及び非従来の投与法の両者による投与、及び/又は細胞治療の補助増強剤として、又は局所適用、又は非経口投与、又は腫瘍内注射、又はそれらの組合せによって投与することを含む、ガン及びガン共存症を治療する方法。   A method of treating cancer and comorbidities including cancer-related fatigue, vicious fluid, loss of appetite, pain, anemia, asthenia, depression, muscle weakness, nausea, vomiting, skin and skin-related tissue damage, and quercetin A composition containing as an active ingredient an extract of Allium species, an extract of Citrus species, an extract of Paulinia species, and an extract of Theobroma species Administered by both conventional and non-conventional methods of administration, and / or as an adjuvant enhancer for cell therapy, or by topical application, or parenteral administration, or intratumoral injection, or a combination thereof A method of treating cancer and cancer comorbidities. 請求項１に記載のガン及びガン共存症を治療する方法において、前記組成物は、クエルセチンを含むアリウム種(Allium species)の抽出物、シトラス種(Citrus species)の抽出物、パウリニア種(Paullinia species)の（微粒化した、又はしていない）抽出物、及びテオブロマ種(Theobroma species)の（微粒化した、又はしていない）抽出物を含んでいる。   2. The method of treating cancer and cancer comorbidities according to claim 1, wherein the composition comprises an extract of Allium species comprising quercetin, an extract of Citrus species, a Paulinia species. ) (Atomized or not) and an extract of theobroma species (atomized or not). 請求項１又は２に記載のガン及びガン共存症を治療する方法において、前記組成物は、４つの活性成分の全質量基準で、クエルセチンを含むアリウム種(Allium species)の抽出物を３０〜９３質量％；シトラス種(Citrus species)の抽出物を３〜３３質量％；パウリニア種(Paullinia species)の（微粒化した、又はしていない）抽出物を０．１０〜２．５質量％；及びテオブロマ種(Theobroma species)の（微粒化した、又はしていない）抽出物を０．１０〜２．５質量％含んでいる。   3. The method of treating cancer and cancer comorbidity according to claim 1 or 2, wherein the composition comprises 30 to 93 extracts of Allium species containing quercetin, based on the total mass of the four active ingredients. 3% to 33% by weight of extract of Citrus species; 0.10 to 2.5% by weight of extract of Paulinia species (micronized or not); and Contains 0.10-2.5% by weight (the finely divided or not) extract of Theobroma species.
JP2016528184A 2013-11-08 2014-11-07 Compositions for use in the treatment of cancer and co-morbidities of cancer Active JP6742904B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361901631P 2013-11-08 2013-11-08
US61/901,631 2013-11-08
PCT/EP2014/074048 WO2015067759A1 (en) 2013-11-08 2014-11-07 Method for the management of cancer and treatment of cancer comorbidities

Publications (3)

Publication Number Publication Date
JP2016535753A true JP2016535753A (en) 2016-11-17
JP2016535753A5 JP2016535753A5 (en) 2019-10-31
JP6742904B2 JP6742904B2 (en) 2020-08-19

Family

ID=51868963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016528184A Active JP6742904B2 (en) 2013-11-08 2014-11-07 Compositions for use in the treatment of cancer and co-morbidities of cancer

Country Status (16)

Country Link
US (2) US10357531B2 (en)
EP (1) EP3065751B1 (en)
JP (1) JP6742904B2 (en)
KR (1) KR102344748B1 (en)
CN (2) CN105682671A (en)
AU (1) AU2014345539B2 (en)
BR (1) BR112016009931B1 (en)
CA (1) CA2928675C (en)
DK (1) DK3065751T3 (en)
ES (1) ES2777250T3 (en)
HK (1) HK1223844A1 (en)
MX (1) MX2016006006A (en)
PL (1) PL3065751T3 (en)
PT (1) PT3065751T (en)
RU (1) RU2016117205A (en)
WO (1) WO2015067759A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2862598A1 (en) 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Use of a composition for the pigmentation of hair and hairs
WO2017186954A1 (en) * 2016-04-28 2017-11-02 Legacy Healthcare Ltd Method for the improvement of speed and endurance capacity
CN113164440A (en) * 2018-11-30 2021-07-23 贝斯以色列女执事医疗中心有限公司 Compositions and methods for reducing major thrombotic events in cancer patients
FR3109881B1 (en) * 2020-05-07 2022-10-21 Legacy Healthcare Switzerland Sa PROCESS FOR IMPROVING THE IMMUN SYSTEM TO ACQUIRE PAN-IMMUNITY
US11819530B1 (en) 2023-05-17 2023-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518361A (en) * 2001-11-27 2005-06-23 ブルジンスキー，スタニスロー・アール A combination of amino acids and riboflavin useful to reduce the toxic effects of cytotoxic chemotherapy
JP2008520544A (en) * 2004-09-17 2008-06-19 ウィノカー、アンドリュー Treatment for cancer-related fatigue
JP2010518180A (en) * 2007-02-13 2010-05-27 レガシー ヘルスケア ホールディング リミテッド Novel cosmetic and / or pharmaceutical compositions and their uses
WO2012113820A1 (en) * 2011-02-23 2012-08-30 Legacy Healthcare Holding Ltd New use of compositions for preventing chemotherapy and radiotherapy induced alopecia (cria), reducing cria impact and improving the appearance of hair re-growth after cria
JP2012530779A (en) * 2009-06-22 2012-12-06 エスケー バイオファーマシューティカルズ カンパニー リミテッド Methods for treating or preventing fatigue
WO2013020719A2 (en) * 2011-08-09 2013-02-14 Legacy Healthcare Holding Ltd New use of compositions to delay the onset of the catagen phase of the hair

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2844614A1 (en) 1978-10-13 1980-05-08 Alfred Czypull Hair growth stimulating colouring compsn. - contg. fragrant vegetable oils, thymol, sodium sulphate, salicylic acid, quinine chloride, camphor, menthol, isopropanol and ethanol
JPH04342517A (en) 1990-07-20 1992-11-30 Yutaka Miyauchi 5alpha-reductase inhibitor and hair tonic containing the sane inhibitor
CH682217A5 (en) 1991-05-23 1993-08-13 Linda Singer Dolla Hair lotion comprising aq. alcoholic extract of natural plant material - and aromatic plant substances and prepn., for treating or preventing baldness
FR2706771A1 (en) 1993-06-21 1994-12-30 Pelletier Jacques Formula for the treatment of certain cancers.
JP3233813B2 (en) 1995-03-31 2001-12-04 株式会社マンダム Tyrosinase biosynthesis promoter, hair cosmetic for improving or preventing gray hair, and cosmetic for sunburn
DE19533777A1 (en) 1995-09-12 1997-03-13 Walther Aria Ellen Hair growth agent contg. garlic, olives, lime juice, and wild camomile flowers
JP3527584B2 (en) 1996-01-23 2004-05-17 株式会社ナリス化粧品 Hair restorer / hair restorer
US5773241A (en) 1996-09-05 1998-06-30 Ericsson; Arthur Dale Preparation of bioactive extracts
JP2000044439A (en) 1998-07-31 2000-02-15 Shiseido Co Ltd Composition for scalp and hair treatment
JP2000247830A (en) 1999-02-26 2000-09-12 Nagase & Co Ltd Elastase inhibitor
EP1228769A1 (en) 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Symbiotic regenerative composition
US6582702B2 (en) * 2001-07-10 2003-06-24 Alvin Foster Rigby Herbal tonic composition that improves respiration, aids in the elimination of toxins and improves overall vitality
US20030077336A1 (en) 2001-10-10 2003-04-24 Maf Group, Llc Anti-inflammatory complex containing flaxseed oil
JP2003201229A (en) 2001-10-23 2003-07-18 Shiseido Co Ltd Matrix metalloprotease activity inhibitor and ageing- resistant cosmetic
BR0203591A (en) * 2002-09-05 2004-05-25 Marc Kipfer Natural rehydrating and energy drink based on coconut water, fruit juices and incorporated nutritional components
DE102004011968A1 (en) 2004-03-10 2005-09-29 Henkel Kgaa Cosmetic or pharmaceutical composition e.g. useful for promoting the growth of desirable skin microorganisms comprises a plant extract with prebiotic activity on the skin
KR20070022018A (en) * 2004-03-19 2007-02-23 네스텍소시에테아노님 Delivery of functional ingredients
MY142017A (en) * 2004-03-19 2010-08-16 Nestec Sa Composition comprising all essential nutrients of a fruit or a plant material with increased stability and bioavailability and process of forming the same
EP1604647B1 (en) 2004-05-12 2008-05-07 Chisso Corporation Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof
WO2005120452A1 (en) 2004-06-07 2005-12-22 Katica Pavlovic A procedure in production of a curative creams for regeneration of skin tissue, easer breathing, psoriasis, pains and tiredness in legs
FR2865132A1 (en) 2004-07-06 2005-07-22 Oreal Use of diosmetin and its derivatives for cosmetic or therapeutic pigmentation of skin and hair, e.g. for treating vitiligo, acts by stimulating melanogenesis
DE202004012348U1 (en) 2004-08-03 2004-10-07 Jabal Amman, Suhbi Hasan Mohammes Composition for skin care in cases of psoriasis or eczema comprises an acidic mixture of onion or garlic, an organic acid and other natural ingredients
JP2006104098A (en) 2004-10-04 2006-04-20 Ichimaru Pharcos Co Ltd Hyaluronidase activity inhibitor
FR2877219B1 (en) 2004-10-28 2007-03-09 Fatima Basri COMPOSITION USED IN COSMETICS OR PHARMACOLOGY TO STIMULATE COLLAGEN SYNTHESIS
FR2877576B1 (en) 2004-11-08 2007-03-09 Ahmed Kadri PHARMACEUTICAL COMPOSITION FOR STIMULATING MASTOCYTE PROLIFERATION AND ACTIVATION
DE102005010142A1 (en) 2005-03-02 2005-11-03 Dr. Kurt Wolff Gmbh & Co. Kg Composition for activating hair roots, especially to combat androgenetic alopecia, containing synergistic combination of caffeine and plant extract with phyto-estrogenic action
JP4804805B2 (en) 2005-06-10 2011-11-02 横関油脂工業株式会社 Cell activator, UV damage relieving agent and melanin production inhibitor
WO2008015341A2 (en) 2006-08-03 2008-02-07 Societe D'extraction Des Principes Actifs Sa (Vincience) Use of a plant extract as active agent for increasing melanin synthesis in melanocytes
WO2008127827A1 (en) * 2007-03-14 2008-10-23 The Hershey Company Health bars and compositions for improving mental and physical energy
US20080305096A1 (en) 2007-06-07 2008-12-11 Unicity International, Inc. Method and composition for providing controlled delivery of biologically active substances
FR2939646B1 (en) 2008-12-12 2017-04-14 Oreal CAPILLARY COLORING PROCESS FROM A COMPOSITION COMPRISING AT LEAST ONE ORTHODIPHENOL, A METAL SALT, HYDROGEN PEROXIDE, (BI) CARBONATE AND ALKALINIZING AGENT
WO2011005311A1 (en) * 2009-07-07 2011-01-13 Robert Shorr Pharmaceutical composition
BR112013002697A2 (en) 2010-08-05 2016-05-31 Legacy Healthcare Holding Ltd method to stimulate hair growth
WO2012140013A2 (en) 2011-04-11 2012-10-18 Legacy Healthcare Holding Ltd New use of compositions for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling.
EP2862598A1 (en) 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Use of a composition for the pigmentation of hair and hairs

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518361A (en) * 2001-11-27 2005-06-23 ブルジンスキー，スタニスロー・アール A combination of amino acids and riboflavin useful to reduce the toxic effects of cytotoxic chemotherapy
JP2008520544A (en) * 2004-09-17 2008-06-19 ウィノカー、アンドリュー Treatment for cancer-related fatigue
JP2010518180A (en) * 2007-02-13 2010-05-27 レガシー ヘルスケア ホールディング リミテッド Novel cosmetic and / or pharmaceutical compositions and their uses
JP2012530779A (en) * 2009-06-22 2012-12-06 エスケー バイオファーマシューティカルズ カンパニー リミテッド Methods for treating or preventing fatigue
WO2012113820A1 (en) * 2011-02-23 2012-08-30 Legacy Healthcare Holding Ltd New use of compositions for preventing chemotherapy and radiotherapy induced alopecia (cria), reducing cria impact and improving the appearance of hair re-growth after cria
WO2013020719A2 (en) * 2011-08-09 2013-02-14 Legacy Healthcare Holding Ltd New use of compositions to delay the onset of the catagen phase of the hair

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
アンドリュー・シェヴァリエ 著, 難波恒雄 監訳, 世界薬用植物百科事典, JPN6019007953, 20 October 2000 (2000-10-20), pages 81, ISSN: 0004183620 *
堀田満ほか編, 世界有用植物事典, JPN6019007952, 25 August 1989 (1989-08-25), pages 63 - 64, ISSN: 0004183621 *
西崎統 監修, ＜改訂版＞健康食品百科, JPN6019007955, 25 March 2003 (2003-03-25), pages 259, ISSN: 0004183619 *

Also Published As

Publication number Publication date
PT3065751T (en) 2020-03-06
AU2014345539A1 (en) 2016-05-19
KR102344748B1 (en) 2021-12-30
AU2014345539A8 (en) 2016-05-26
RU2016117205A (en) 2017-12-11
CA2928675A1 (en) 2015-05-14
EP3065751B1 (en) 2019-12-18
US20190314441A1 (en) 2019-10-17
ES2777250T3 (en) 2020-08-04
WO2015067759A1 (en) 2015-05-14
PL3065751T3 (en) 2020-07-13
CA2928675C (en) 2023-09-05
EP3065751A1 (en) 2016-09-14
RU2016117205A3 (en) 2018-08-09
CN105682671A (en) 2016-06-15
US10357531B2 (en) 2019-07-23
AU2014345539B2 (en) 2020-04-23
JP6742904B2 (en) 2020-08-19
DK3065751T3 (en) 2020-03-09
MX2016006006A (en) 2016-07-18
KR20160074006A (en) 2016-06-27
US20160256512A1 (en) 2016-09-08
CN115350236A (en) 2022-11-18
BR112016009931B1 (en) 2021-02-02
HK1223844A1 (en) 2017-08-11

Similar Documents

Publication Publication Date Title
JP6742904B2 (en) Compositions for use in the treatment of cancer and co-morbidities of cancer
Ariel Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors
BR112012020185A2 (en) use of oral heparin preparations to treat urinary tract diseases and disorders.
EP3391893A1 (en) Medicine composition for treating leukemia and preparation method therefor
JP5841903B2 (en) Drugs for treatment of liver damage or improvement of liver function
CN105982887A (en) Application of arctigenin in preparing medicine for treating blood hyperviscosity
Ghaffarie et al. Effect of hydroalcoholic extract of cinnamon on the pituitary-gonadal axis in adult male rats under chemotherapy by cyclophosphamide
JP7376678B2 (en) Cancer cell-targeting drug delivery body and composition for enhancing photothermal treatment effect containing M1 macrophages as an active ingredient
TWI462918B (en) Novel uses of colossolactones
KR20120102214A (en) A medicine for external application of natural and oriental herb complex
CN1022020C (en) Tobacco additive and its prepairing method
EP3829615B1 (en) Composition for oral administration comprising one or more cannabinoids
CN106668039A (en) Drug composition for treating neurasthenia
WO2016124605A1 (en) Compositions comprising melatonin for preventing and treating pulmonary injury due to ionizing radiation or cytotoxic drugs
CN105232658A (en) Stasis removing and pain relieving traditional Chinese medicine preparation for treating glioma and preparation method thereof
Shi et al. Journal of Experimental and Clinical Application of Chinese Medicine
CN103239670B (en) Chinese medicine effective part composition for treating breast hyperplasia and preparation method of Chinese medicine effective part composition
JP2024017060A (en) Tie2 activator
TW202211914A (en) Pharmaceutical compositions for treating arthritis and preparation methods thereof
CN113209244A (en) Traditional Chinese medicine composition for treating pancreatic cancer
Pilkington et al. Ozone therapy
WO2016210409A1 (en) L-carnosine zinc formulations and methods of use
CN107375299A (en) A kind of new application of asiatic acid and the antitumor combination containing asiatic acid
WO2017204685A1 (en) Bifunctional composition for treating diseases of musculoskeletal apparatus
Berry PURPORTED USES Cancer Heart disease Stroke Diarrhea

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171010

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190912

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200507

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200721

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200729

R150 Certificate of patent or registration of utility model

Ref document number: 6742904

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250